Navigation Links
EntreMed Announces Changes to Board of Directors and CEO Appointment
Date:4/5/2013

sed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.  EntreMed, Inc. recently initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer.

Forward Looking Statements           

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
2. EntreMed To Raise $10.7 Million In Registered Direct Offering
3. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
4. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
6. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
7. EntreMed Reports Second Quarter 2012 Financial Results
8. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
9. EntreMed Reports First Quarter 2012 Financial Results
10. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
11. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... SPRINGDALE, Ark. , Sept. 1, 2015 NOWDiagnostics Inc., ... completed its acquisition of ZBx Corporation of Canada ... to its vision of a world where people have ... NOWDiagnostics manufactures and sells a line of unique blood-based ... simple-to-use, highly accurate tests for a variety of ailments ...
(Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
(Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... in wake of AHA-presented data , ... a clinical trial suggesting rosuvastatin may lower the cardiovascular risk ... statin use in older adults, according to a national poll ... the online poll conducted by medical news site MedPage Today ...
... FRANCISCO, Calif., Nov. 25 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... on,innovative oncology therapies, announced today that it will ... in order to allow,the Company to focus its ... product candidate, and to support the initial commercialization ...
Cached Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3
(Date:9/1/2015)... Miami, FL (PRWEB) , ... September 01, 2015 ... ... Food and Drug Administration (FDA) for the treatment of androgenic alopecia in adults, ... the brand new laser therapy cap, while also demonstrating its safety when used ...
(Date:9/1/2015)... ... September 01, 2015 , ... According to a ... with type 2 diabetes that participated in a three year study about weight loss ... the line if they elected weight loss surgery at the onset of the trial. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... managed, stress created from everyday life changes can lead to very serious, life-altering ... support for coping with stress. Herbal supplement manufacturer MediHerb has coupled ...
(Date:9/1/2015)... ... ... Philanthropic giving in the U.S. has been stuck at 2% GDP since the ... today by Camber Collective, goes to the root of this problem and provides a ... new philanthropic giving and shift $25B that’s already being donated, according to the report. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... cure and prevent different malignancies. Some options for cancer treatment are available ... to which distinctive approach is necessary for effective treatment. Several molecules have ...
Breaking Medicine News(10 mins):Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3
... Ill., Feb. 29 Landauer, Inc. (NYSE:,LDR) announced today ... dividend of $0.50 per share for the second quarter ... 4, 2008, to shareholders of record,on March 14, 2008., ... of analytical services to determine,occupational and environmental radiation exposure. ...
... Genoptix, Inc.,(Nasdaq: GXDX ), today announced the ... by certain existing stockholders to,the public at the price ... proceeds from the sale. The offer is expected to ... made through an underwriting syndicate led by,Lehman Brothers, Inc. ...
... Xing,Mobile Communication Co., Ltd. (,Qiao Xing Mobile, or ,the ... manufacturers of mobile,handsets through its subsidiary CEC Telecom Co., ... cardiograph mobile handset., The C7000A has the ... be able to perform a basic ...
... respiratory diseases like chronic bronchitis, but genes also play ... in Sweden, who studied more than 40,000 Swedish twins ... genes each play a role ion the development of ... known genetic component and smoking is a primary risk ...
... TULSA, Okla., Feb. 28 Presidential campaign fever is,running ... can,t hold a,candle to the presidential star power that ... Saturday night, March 1st, when they host the 16th,President ... Mr. Lincoln will be addressing Tulsa,s top doctors ...
... blood thinner continues , , THURSDAY, Feb. 28 (HealthDay News) ... center of recent problems with its blood thinner heparin, ... vials of the drug as well as single-dose vials. ... Hep-Lock heparin flush products, which contain a small amount ...
Cached Medicine News:Health News:Genoptix Announces Pricing of Secondary Public Offering 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 3Health News:Genetic factors in smoking also increase risk of chronic bronchitis 2Health News:Baxter Recalls Rest of Heparin Products 2Health News:Baxter Recalls Rest of Heparin Products 3
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Medicine Products: